Sleep Data Might Change The Case For Investing In Alkermes Stock (ALKS)

• Alkermes reported that it shared new clinical data on Alixorexton from the Vibrance 1 Phase 2 and extension studies in narcolepsy and on LUMRYZ from the Phase 3 REVITALYZ trial in idiopathic hypersomnia at Sleep Europe 2026, reinforcing its focus on sleep and neurological disorders.
• The fresh Alixorexton and LUMRYZ data gives investors more clarity on how Alkermes is working to build a broader orexin based sleep franchise around its existing neuroscience portfolio.
• Next, the focus turns to how Alkermes' new Alixorexton and LUMRYZ sleep data might reshape the existing investment narrative around its orexin portfolio.

Compare Alkermes' orexin focused progress with other sleep and neurology players by scanning our curated list of 33 healthcare AI stocks for potential under-the-radar opportunities in this space.

Alkermes Investment Narrative Recap

To own Alkermes, you need to be comfortable with a story where the existing psychiatry and addiction portfolio funds a heavy push into orexin based sleep and neurology therapies. The recent Alixorexton and LUMRYZ data at Sleep Europe 2026 supports that focus but does not radically change the near term setup. The key near term catalyst still sits in later stage orexin studies and potential label expansion work.

The biggest tension in the Alkermes thesis is simple. Management is guiding to a GAAP net loss of US$95 million to US$115 million in 2026 while R&D and integration costs stay elevated. If late stage trials such as Brilliance or future Vibrance work disappoint, that spending could bite just as valuations already assume meaningful orexin success.

The most relevant recent update tied to this news is the positive Phase 3 REVITALYZ data for LUMRYZ in idiopathic hypersomnia and the plan to file a supplemental NDA by year end 2026. That decision connects directly with the newer Sleep Europe 2026 readouts because both focus on turning the LUMRYZ and orexin platform into a broader sleep franchise.

For you as a shareholder, that filing timeline matters. It adds a clear regulatory milestone on top of ongoing programs like Vibrance and Brilliance. Progress here is pulling Alkermes deeper into central disorders of hypersomnolence while the existing VIVITROL, ARISTADA and LYBALVI portfolio continues to fund the effort. The trade off remains execution risk against the prospect of a more diversified neuroscience business.

Alkermes Orexin Outlook Through The Numbers

Alkermes' narrative projects US$2.3b revenue and US$363.0 million earnings by 2029. This assumes 10.6% yearly revenue growth and an earnings increase of about US$297 million from US$66.1 million today.

Uncover why Alkermes' fair value indicates a 42% potential upside to its current price, a gap that may not last much longer.

Exploring Other Perspectives

One alternate view you may want to test against this new Alkermes sleep data focuses on earnings risk. The most cautious analysts were modeling revenue of about US$2.0b and earnings near US$346.5 million by 2029, while some projected a loss of roughly US$67.5 million. That spread shows how sharply expectations can differ and why it can help to review several narratives before deciding what the new orexin updates might mean for you.

Explore 4 other Alkermes fair value estimates, including one that suggests it could be worth just $38.20.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alkermes research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• See our latest analysis for Alkermes. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Alkermes' overall financial health at a glance.

Looking For More Investment Ideas Beyond Alkermes?

If the Alkermes story has sharpened your interest in sleep, neurology and broader healthcare themes, it can help to line it up against other potential opportunities on your watchlist. The Simply Wall St Screener gives you a structured way to compare quality, risk and income across a wide universe of stocks so you can see where Alkermes fits in your broader plan.

• For investors who want potential mispricings backed by solid fundamentals, review our 32 high quality undervalued stocks that may warrant a closer look.
• If resilience matters most to you, filter for 32 resilient stocks with low risk scores that score well on stability and balance sheet strength.
• For those hunting for under-followed opportunities, scan the 20 high quality undiscovered gems that combine quality metrics with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com